CSF neurogranin levels as a biomarker in Alzheimer's disease and frontotemporal lobar degeneration: a cross-sectional analysis.
Humans
Female
Male
Alzheimer Disease
/ cerebrospinal fluid
Aged
Neurogranin
/ cerebrospinal fluid
Frontotemporal Lobar Degeneration
/ cerebrospinal fluid
Biomarkers
/ cerebrospinal fluid
Cross-Sectional Studies
Cognitive Dysfunction
/ cerebrospinal fluid
Middle Aged
Apolipoproteins E
/ genetics
Aged, 80 and over
Neuropsychological Tests
Amyloid beta-Peptides
/ cerebrospinal fluid
APOE
Alzheimer’s disease
Frontotemporal lobar degeneration
Memory
Neurogranin
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
06 Sep 2024
06 Sep 2024
Historique:
received:
05
07
2024
accepted:
24
08
2024
medline:
7
9
2024
pubmed:
7
9
2024
entrez:
6
9
2024
Statut:
epublish
Résumé
There is initial evidence suggesting that biomarker neurogranin (Ng) may distinguish Alzheimer's disease (AD) from other neurodegenerative diseases. Therefore, we assessed (a) the discriminant ability of cerebrospinal fluid (CSF) Ng levels to distinguish between AD and frontotemporal lobar degeneration (FTLD) pathology and between different stages within the same disease, (b) the relationship between Ng levels and cognitive performance in both AD and FTLD pathology, and (c) whether CSF Ng levels vary by apolipoprotein E (APOE) polymorphism in the AD continuum. Participants with subjective cognitive decline (SCD) (n = 33), amnestic mild cognitive impairment (aMCI) due to AD (n = 109), AD dementia (n = 67), MCI due to FTLD (n = 25), and FTLD dementia (n = 29) were recruited from the Czech Brain Aging Study. One-way analysis of covariance (ANCOVA) assessed Ng levels in diagnostic subgroups. Linear regressions evaluated the relationship between CSF Ng levels, memory scores, and APOE polymorphism. Ng levels were higher in aMCI-AD patients compared to MCI-FTLD (F[1, 134] = 15.16, p < .001), and in AD-dementia compared to FTLD-dementia (F[1, 96] = 4.60, p = .029). Additionally, Ng levels were higher in FTLD-dementia patients compared to MCI-FTLD (F[1, 54]= 4.35, p = .034), lower in SCD participants compared to aMCI-AD (F[1, 142] = 10.72, p = .001) and AD-dementia (F[1, 100] = 20.90, p < .001), and did not differ between SCD participants and MCI-FTLD (F[1, 58]= 1.02, p = .491) or FTLD-dementia (F[1, 62]= 2.27, p = .051). The main effect of diagnosis across the diagnostic subgroups on Aβ In this first study to-date to assess MCI and dementia due to AD or FTLD within one study, elevated CSF Ng appears to be an early biomarker of AD-related impairment, but its role as a biomarker appears to diminish after dementia diagnosis, whereby dementia-related underlying processes in AD and FTLD may begin to merge. The Aβ
Sections du résumé
BACKGROUND
BACKGROUND
There is initial evidence suggesting that biomarker neurogranin (Ng) may distinguish Alzheimer's disease (AD) from other neurodegenerative diseases. Therefore, we assessed (a) the discriminant ability of cerebrospinal fluid (CSF) Ng levels to distinguish between AD and frontotemporal lobar degeneration (FTLD) pathology and between different stages within the same disease, (b) the relationship between Ng levels and cognitive performance in both AD and FTLD pathology, and (c) whether CSF Ng levels vary by apolipoprotein E (APOE) polymorphism in the AD continuum.
METHODS
METHODS
Participants with subjective cognitive decline (SCD) (n = 33), amnestic mild cognitive impairment (aMCI) due to AD (n = 109), AD dementia (n = 67), MCI due to FTLD (n = 25), and FTLD dementia (n = 29) were recruited from the Czech Brain Aging Study. One-way analysis of covariance (ANCOVA) assessed Ng levels in diagnostic subgroups. Linear regressions evaluated the relationship between CSF Ng levels, memory scores, and APOE polymorphism.
RESULTS
RESULTS
Ng levels were higher in aMCI-AD patients compared to MCI-FTLD (F[1, 134] = 15.16, p < .001), and in AD-dementia compared to FTLD-dementia (F[1, 96] = 4.60, p = .029). Additionally, Ng levels were higher in FTLD-dementia patients compared to MCI-FTLD (F[1, 54]= 4.35, p = .034), lower in SCD participants compared to aMCI-AD (F[1, 142] = 10.72, p = .001) and AD-dementia (F[1, 100] = 20.90, p < .001), and did not differ between SCD participants and MCI-FTLD (F[1, 58]= 1.02, p = .491) or FTLD-dementia (F[1, 62]= 2.27, p = .051). The main effect of diagnosis across the diagnostic subgroups on Aβ
CONCLUSIONS
CONCLUSIONS
In this first study to-date to assess MCI and dementia due to AD or FTLD within one study, elevated CSF Ng appears to be an early biomarker of AD-related impairment, but its role as a biomarker appears to diminish after dementia diagnosis, whereby dementia-related underlying processes in AD and FTLD may begin to merge. The Aβ
Identifiants
pubmed: 39242539
doi: 10.1186/s13195-024-01566-w
pii: 10.1186/s13195-024-01566-w
doi:
Substances chimiques
Neurogranin
132654-77-4
Biomarkers
0
Apolipoproteins E
0
Amyloid beta-Peptides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
199Informations de copyright
© 2024. The Author(s).
Références
Kukull WA, Bowen JD. Dementia epidemiology. Med Clin North Am. 2002;86:573–90.
pubmed: 12168560
doi: 10.1016/S0025-7125(02)00010-X
DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener. 2019;14:32.
pubmed: 31375134
pmcid: 6679484
doi: 10.1186/s13024-019-0333-5
Seelaar H, Rohrer JD, Pijnenburg YAL, Fox NC, van Swieten JC. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J Neurol Neurosurg Psychiatry. 2011;82:476–86.
pubmed: 20971753
doi: 10.1136/jnnp.2010.212225
Antonioni A, Raho EM, Lopriore P, Pace AP, Latino RR, Assogna M et al. Frontotemporal Dementia, where do we stand? A narrative review. Int J Mol Sci. 2023;24.
Boxer AL, Gold M, Huey E, Gao F-B, Burton EA, Chow T, et al. Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development. Alzheimers Dement. 2013;9:176–88.
pubmed: 23043900
doi: 10.1016/j.jalz.2012.03.002
Represa A, Deloulme JC, Sensenbrenner M, Ben-Ari Y, Baudier J. Neurogranin: immunocytochemical localization of a brain-specific protein kinase C substrate. J Neurosci. 1990;10:3782–92.
pubmed: 2269883
pmcid: 6570038
doi: 10.1523/JNEUROSCI.10-12-03782.1990
Clarke MTM, Brinkmalm A, Foiani MS, Woollacott IOC, Heller C, Heslegrave A, et al. CSF synaptic protein concentrations are raised in those with atypical Alzheimer’s disease but not frontotemporal dementia. Alzheimers Res Ther. 2019;11:105.
pubmed: 31847891
pmcid: 6918699
doi: 10.1186/s13195-019-0564-2
Janelidze S, Hertze J, Zetterberg H, Landqvist Waldö M, Santillo A, Blennow K, et al. Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer’s disease. Ann Clin Transl Neurol. 2016;3:12–20.
pubmed: 26783546
doi: 10.1002/acn3.266
Wellington H, Paterson RW, Portelius E, Törnqvist U, Magdalinou N, Fox NC, et al. Increased CSF neurogranin concentration is specific to Alzheimer disease. Neurology. 2016;86:829–35.
pubmed: 26826204
pmcid: 4793782
doi: 10.1212/WNL.0000000000002423
Portelius E, Olsson B, Höglund K, Cullen NC, Kvartsberg H, Andreasson U, et al. Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. Acta Neuropathol. 2018;136:363–76.
pubmed: 29700597
pmcid: 6096740
doi: 10.1007/s00401-018-1851-x
Kvartsberg H, Duits FH, Ingelsson M, Andreasen N, Öhrfelt A, Andersson K, et al. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer’s disease. Alzheimers Dement. 2015;11:1180–90.
pubmed: 25533203
doi: 10.1016/j.jalz.2014.10.009
Kulczyńska-Przybik A, Dulewicz M, Doroszkiewicz J, Borawska R, Słowik A, Zetterberg H et al. The relationships between Cerebrospinal Fluid Glial (CXCL12, CX3CL, YKL-40) and synaptic biomarkers (Ng, NPTXR) in early Alzheimer’s Disease. Int J Mol Sci. 2023;24.
Kester MI, Teunissen CE, Crimmins DL, Herries EM, Ladenson JH, Scheltens P, et al. Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic Alzheimer Disease. JAMA Neurol. 2015;72:1275–80.
pubmed: 26366630
pmcid: 4694558
doi: 10.1001/jamaneurol.2015.1867
Piccoli T, Blandino V, Maniscalco L, Matranga D, Graziano F, Guajana F et al. Biomarkers related to synaptic dysfunction to Discriminate Alzheimer’s Disease from Other Neurological disorders. Int J Mol Sci. 2022;23.
Pak JH, Huang FL, Li J, Balschun D, Reymann KG, Chiang C, et al. Involvement of neurogranin in the modulation of calcium/calmodulin-dependent protein kinase II, synaptic plasticity, and spatial learning: a study with knockout mice. Proc Natl Acad Sci U S A. 2000;97:11232–7.
pubmed: 11016969
pmcid: 17183
doi: 10.1073/pnas.210184697
Headley A, De Leon-Benedetti A, Dong C, Levin B, Loewenstein D, Camargo C, et al. Neurogranin as a predictor of memory and executive function decline in MCI patients. Neurology. 2018;90:e887–95.
pubmed: 29429972
pmcid: 5863492
doi: 10.1212/WNL.0000000000005057
Pereira JB, Janelidze S, Ossenkoppele R, Kvartsberg H, Brinkmalm A, Mattsson-Carlgren N, et al. Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease. Brain. 2021;144:310–24.
pubmed: 33279949
doi: 10.1093/brain/awaa395
Casaletto KB, Elahi FM, Bettcher BM, Neuhaus J, Bendlin BB, Asthana S, et al. Neurogranin, a synaptic protein, is associated with memory independent of Alzheimer biomarkers. Neurology. 2017;89:1782–8.
pubmed: 28939668
pmcid: 5664306
doi: 10.1212/WNL.0000000000004569
Teter B. ApoE-dependent plasticity in Alzheimer’s disease. J Mol Neurosci. 2004;23:167–79.
pubmed: 15181245
doi: 10.1385/JMN:23:3:167
Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A. 2000;97:2892–7.
pubmed: 10694577
pmcid: 16026
doi: 10.1073/pnas.050004797
Tannenberg RK, Scott HL, Tannenberg AEG, Dodd PR. Selective loss of synaptic proteins in Alzheimer’s disease: evidence for an increased severity with APOE varepsilon4. Neurochem Int. 2006;49:631–9.
pubmed: 16814428
doi: 10.1016/j.neuint.2006.05.004
Weeber EJ, Beffert U, Jones C, Christian JM, Forster E, Sweatt JD, et al. Reelin and ApoE receptors cooperate to enhance hippocampal synaptic plasticity and learning. J Biol Chem. 2002;277:39944–52.
pubmed: 12167620
doi: 10.1074/jbc.M205147200
Dumanis SB, Tesoriero JA, Babus LW, Nguyen MT, Trotter JH, Ladu MJ, et al. ApoE4 decreases spine density and dendritic complexity in cortical neurons in vivo. J Neurosci. 2009;29:15317–22.
pubmed: 19955384
pmcid: 2846754
doi: 10.1523/JNEUROSCI.4026-09.2009
Butt OH, Long JM, Henson RL, Herries E, Sutphen CL, Fagan AM, et al. Cognitively normal APOE ε4 carriers have specific elevation of CSF SNAP-25. Neurobiol Aging. 2021;102:64–72.
pubmed: 33765432
pmcid: 8793109
doi: 10.1016/j.neurobiolaging.2021.02.008
Wang L, Alzheimer’s Disease Neuroimaging Initiative. Association of cerebrospinal fluid neurogranin with Alzheimer’s disease. Aging Clin Exp Res. 2019;31:185–91.
pubmed: 29667155
doi: 10.1007/s40520-018-0948-3
Sheardova K, Vyhnalek M, Nedelska Z, Laczo J, Andel R, Marciniak R, et al. Czech Brain Aging Study (CBAS): prospective multicentre cohort study on risk and protective factors for dementia in the Czech Republic. BMJ Open. 2019;9:e030379.
pubmed: 31857299
pmcid: 6937049
doi: 10.1136/bmjopen-2019-030379
Hort J, Glosova L, Vyhnalek M, Bojar M, Skoda D, Hladikova M. The liquor tau protein and beta amyloid in Alzheimer’s disease. Česká Slovenská Neurologie Neurochirurgie. 2007;70:30–6.
Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chételat G, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement. 2014;10:844–52.
pubmed: 24798886
doi: 10.1016/j.jalz.2014.01.001
Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:270–9.
pubmed: 21514249
doi: 10.1016/j.jalz.2011.03.008
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9.
pubmed: 21514250
doi: 10.1016/j.jalz.2011.03.005
Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456–77.
pubmed: 21810890
pmcid: 3170532
doi: 10.1093/brain/awr179
Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006–14.
pubmed: 21325651
pmcid: 3059138
doi: 10.1212/WNL.0b013e31821103e6
Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183–94.
pubmed: 15324362
doi: 10.1111/j.1365-2796.2004.01388.x
Sorbi S, Hort J, Erkinjuntti T, Fladby T, Gainotti G, Gurvit H, et al. EFNS-ENS guidelines on the diagnosis and management of disorders associated with dementia. Eur J Neurol. 2012;19:1159–79.
pubmed: 22891773
doi: 10.1111/j.1468-1331.2012.03784.x
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA, American Psychiatric Association, 2013.
Stepankova H, Nikolai T, Lukavsky J, Bezdicek O, Vrajova M, Kopecek M. Mini–Mental State examination – Czech normative study. Čes Slov Neurol Neurochir. 2015;78/111:57–63.
Nikolai T, Stepankova H, Kopecek M, Sulc Z, Vyhnalek M, Bezdicek O. Normative Data in Older Adults from an International Perspective. J Alzheimers Dis. 2018;61:1233–40. The Uniform Data Set, Czech Version:.
Bezdicek O, Motak L, Axelrod BN, Preiss M, Nikolai T, Vyhnalek M, et al. Czech version of the trail making test: normative data and clinical utility. Arch Clin Neuropsychol. 2012;27:906–14.
pubmed: 23027441
doi: 10.1093/arclin/acs084
Drozdova K, Stepankova H, Lukavsky J, Bezdicek O, Kopecek M. Normative data for the rey-osterrieth complex figure test in older Czech adults. Ceska Slov Neurologie Neurochirurgie. 2015;78:542–9.
Zemanova N, Bezdicek O, Michalec J, Nikolai T, Roth J, Jech R, Ruzicka E. Validity study of the Boston naming Test Czech version. Ceska Slov Neurologie Neurochirurgie. 2016;79/112:307–16.
Nikolai T, Štěpánková H, Michalec J, Bezdíček O, Horáková K, Marková H, et al. Testy verbální fluence, česká normativní studie pro osoby vyššího věku. Ceska Slov Neurologie Neurochirurgie. 2015;78:292–9.
doi: 10.14735/amcsnn2015292
Benton A, Hamsher K. Multilingual aphasia examination. University of Iowa; 1976.
Mazancova AF, Nikolai T, Stepankova H, Kopecek M, Bezdicek O. The reliability of clock drawing test Scoring systems modeled on the normative data in healthy aging and nonamnestic mild cognitive impairment. Assessment. 2017;24:945–57.
pubmed: 26933141
doi: 10.1177/1073191116632586
Gobom J, Parnetti L, Rosa-Neto P, Vyhnalek M, Gauthier S, Cataldi S, et al. Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. Clin Chem Lab Med. 2022;60:207–19.
pubmed: 34773730
doi: 10.1515/cclm-2021-0651
Laczó J, Andel R, Vlček K, Mat’oška V, Vyhnálek M, Tolar M, et al. Spatial navigation and APOE in amnestic mild cognitive impairment. Neurodegener Dis. 2011;8:169–77.
pubmed: 21124005
doi: 10.1159/000321581
Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990;31:545–8.
pubmed: 2341813
doi: 10.1016/S0022-2275(20)43176-1
Cohen J. Statistical power analysis for the behavioral sciences. 2 ed. Hillsdale: Lawrence Erlbaum Associates; 1988.
Nahm FS. Receiver operating characteristic curve: overview and practical use for clinicians. Korean J Anesthesiol. 2022;75:25–36.
pubmed: 35124947
pmcid: 8831439
doi: 10.4097/kja.21209
Bogdanovic N, Davidsson P, Gottfries J, Volkman I, Winblad B, Blennow K. Regional and Cellular distribution of synaptic proteins in the normal human brain. Brain Aging. 2002;2:18–30.
Falgàs N, Ruiz-Peris M, Pérez-Millan A, Sala-Llonch R, Antonell A, Balasa M, et al. Contribution of CSF biomarkers to early-onset Alzheimer’s disease and frontotemporal dementia neuroimaging signatures. Hum Brain Mapp. 2020;41:2004–13.
pubmed: 31944489
pmcid: 7267898
doi: 10.1002/hbm.24925
Nilsson J, Cousins KAQ, Gobom J, Portelius E, Chen-Plotkin A, Shaw LM, et al. Cerebrospinal fluid biomarker panel of synaptic dysfunction in Alzheimer’s disease and other neurodegenerative disorders. Alzheimers Dement. 2023;19:1775–84.
pubmed: 36239248
doi: 10.1002/alz.12809
Antonell A, Tort-Merino A, Ríos J, Balasa M, Borrego-Écija S, Auge JM, et al. Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias. Alzheimers Dement. 2020;16:262–72.
pubmed: 31668967
doi: 10.1016/j.jalz.2019.09.001
Hampel H, Toschi N, Baldacci F, Zetterberg H, Blennow K, Kilimann I, et al. Alzheimer’s disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ1–42, total-tau, phosphorylated-tau, NFL, neurogranin, and YKL-40. Alzheimers Dement. 2018;14:492–501.
pubmed: 29328927
doi: 10.1016/j.jalz.2017.11.015
Lista S, Toschi N, Baldacci F, Zetterberg H, Blennow K, Kilimann I, et al. Cerebrospinal fluid neurogranin as a biomarker of neurodegenerative diseases: a cross-sectional study. J Alzheimers Dis. 2017;59:1327–34.
pubmed: 28731449
doi: 10.3233/JAD-170368
Mavroudis IA, Petridis F, Chatzikonstantinou S, Kazis D. A meta-analysis on CSF neurogranin levels for the diagnosis of Alzheimer’s disease and mild cognitive impairment. Aging Clin Exp Res. 2020;32:1639–46.
pubmed: 31463927
doi: 10.1007/s40520-019-01326-z
Morar U, Izquierdo W, Martin H, Forouzannezhad P, Zarafshan E, Unger E, et al. A study of the longitudinal changes in multiple cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers on converter and non-converter Alzheimer’s disease subjects with consideration for their amyloid beta status. Alzheimers Dement (Amst). 2022;14:e12258.
pubmed: 35229014
doi: 10.1002/dad2.12258
Dulewicz M, Kulczyńska-Przybik A, Borawska R, Słowik A, Mroczko B. Evaluation of synaptic and axonal dysfunction biomarkers in Alzheimer’s disease and mild cognitive impairment based on CSF and Bioinformatic Analysis. Int J Mol Sci. 2022;23.
Liu W, Lin H, He X, Chen L, Dai Y, Jia W, et al. Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer’s disease and mild cognitive impairment. Transl Psychiatry. 2020;10:125.
pubmed: 32350238
pmcid: 7190828
doi: 10.1038/s41398-020-0801-2
Wang Z, Yang J, Zhu W, Tang Y, Jia J. The synaptic marker neurogranin as a disease state biomarker in Alzheimer’s disease: a systematic review and meta-analysis. Int J Neurosci. 2022;132:1245–53.
pubmed: 33527855
doi: 10.1080/00207454.2021.1881087
Álvarez I, Diez-Fairen M, Aguilar M, González JM, Ysamat M, Tartari JP, et al. Added value of cerebrospinal fluid multimarker analysis in diagnosis and progression of dementia. Eur J Neurol. 2021;28:1142–52.
pubmed: 33236496
doi: 10.1111/ene.14658
Hellwig K, Kvartsberg H, Portelius E, Andreasson U, Oberstein TJ, Lewczuk P, et al. Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer’s disease. Alzheimers Res Ther. 2015;7:74.
pubmed: 26698298
pmcid: 4690296
doi: 10.1186/s13195-015-0161-y
De Vos A, Jacobs D, Struyfs H, Fransen E, Andersson K, Portelius E, et al. C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer’s disease. Alzheimers Dement. 2015;11:1461–9.
pubmed: 26092348
doi: 10.1016/j.jalz.2015.05.012
Xue M, Sun F-R, Ou Y-N, Shen X-N, Li H-Q, Huang Y-Y, et al. Association of cerebrospinal fluid neurogranin levels with cognition and neurodegeneration in Alzheimer’s disease. Aging. 2020;12:9365–79.
pubmed: 32421689
pmcid: 7288926
doi: 10.18632/aging.103211
Tarawneh R, D’Angelo G, Crimmins D, Herries E, Griest T, Fagan AM, et al. Diagnostic and Prognostic Utility of the synaptic marker neurogranin in Alzheimer Disease. JAMA Neurol. 2016;73:561–71.
pubmed: 27018940
pmcid: 4861689
doi: 10.1001/jamaneurol.2016.0086
Portelius E, Zetterberg H, Skillbäck T, Törnqvist U, Andreasson U, Trojanowski JQ, et al. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer’s disease. Brain. 2015;138:3373–85.
pubmed: 26373605
pmcid: 4643642
doi: 10.1093/brain/awv267
Das S, Goossens J, Jacobs D, Dewit N, Pijnenburg YAL, I’tV SGJG, et al. Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer’s disease and frontotemporal dementia. Alzheimers Res Ther. 2023;15:62.
pubmed: 36964594
pmcid: 10037899
doi: 10.1186/s13195-023-01212-x
Petersen A, Gerges NZ. Neurogranin regulates CaM dynamics at dendritic spines. Sci Rep. 2015;5:11135.
pubmed: 26084473
pmcid: 4471661
doi: 10.1038/srep11135
Rådestig MA, Skoog J, Zetterberg H, Skillbäck T, Zettergren A, Sterner TR, et al. Subtle differences in Cognition in 70-Year-Olds with elevated cerebrospinal fluid neurofilament light and neurogranin: a H70 cross-sectional study. J Alzheimers Dis. 2023;91:291–303.
pubmed: 36617786
pmcid: 9881027
doi: 10.3233/JAD-220452
Liu C-C, Liu C-C, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9:106–18.
pubmed: 23296339
pmcid: 3726719
doi: 10.1038/nrneurol.2012.263
Sun X, Dong C, Levin B, Crocco E, Loewenstein D, Zetterberg H, et al. APOE ε4 carriers may undergo synaptic damage conferring risk of Alzheimer’s disease. Alzheimers Dement. 2016;12:1159–66.
pubmed: 27321472
doi: 10.1016/j.jalz.2016.05.003
Bos I, Vos S, Verhey F, Scheltens P, Teunissen C, Engelborghs S, et al. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer’s disease spectrum. Alzheimers Dement. 2019;15:644–54.
pubmed: 30853464
doi: 10.1016/j.jalz.2019.01.004
Lista S, Hampel H. Synaptic degeneration and neurogranin in the pathophysiology of Alzheimer’s disease. Expert Rev Neurother. 2017;17:47–57.
pubmed: 27332958
doi: 10.1080/14737175.2016.1204234
Camporesi E, Nilsson J, Brinkmalm A, Becker B, Ashton NJ, Blennow K, et al. Fluid biomarkers for synaptic dysfunction and loss. Biomark Insights. 2020;15:1177271920950319.
pubmed: 32913390
pmcid: 7444114
doi: 10.1177/1177271920950319
Zetterberg H, Skillbäck T, Mattsson N, Trojanowski JQ, Portelius E, Shaw LM, et al. Association of Cerebrospinal Fluid Neurofilament Light Concentration with Alzheimer Disease Progression. JAMA Neurol. 2016;73:60.
pubmed: 26524180
pmcid: 5624219
doi: 10.1001/jamaneurol.2015.3037
Kim KY, Shin KY, Chang K-A. GFAP as a potential biomarker for Alzheimer’s Disease: a systematic review and Meta-analysis. Cells. 2023;12:1309.
pubmed: 37174709
pmcid: 10177296
doi: 10.3390/cells12091309
Massa F, Halbgebauer S, Barba L, Oeckl P, Gómez de San José N, Bauckneht M, et al. Exploring the brain metabolic correlates of process-specific CSF biomarkers in patients with MCI due to Alzheimer’s disease: preliminary data. Neurobiol Aging. 2022;117:212–21.
pubmed: 35780561
doi: 10.1016/j.neurobiolaging.2022.03.019
Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019;90:870–81.
pubmed: 30967444
doi: 10.1136/jnnp-2018-320106